Introduction: Ongoing clinical challenges in the management of meningiomas and future directions

Justin Z Wang^{1

2

3}, Farshad Nassiri^{1

2

3}, Kenneth Aldape⁴, Gelareh Zadeh^{1

2

3}

Affiliations

¹ MacFeeters Hamilton Neuro-Oncology Program, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, Ontario, Canada.
² Division of Neurosurgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
³ Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
⁴ Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

Justin Z Wang et al. Neurooncol Adv. 2023.

. 2023 Jun 3;5(Suppl 1):i1-i4.

doi: 10.1093/noajnl/vdad030. eCollection 2023 May.

Justin Z Wang^{1

2

3}, Farshad Nassiri^{1

2

3}, Kenneth Aldape⁴, Gelareh Zadeh^{1

2

3}

¹ MacFeeters Hamilton Neuro-Oncology Program, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, Ontario, Canada.
² Division of Neurosurgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
³ Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
⁴ Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

No abstract available

Figures

1. Ostrom QT, Price M, Neff C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015-2019. Neuro Oncol. 2022;24(Suppl 5):v1–v95. - PMC - PubMed
1. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–820. - PubMed
1. Suppiah S, Nassiri F, Bi WL, et al. Molecular and translational advances in meningiomas. Neuro-oncology. 2019;21(Supplement_1):i4–i17. - PMC - PubMed
1. Biczok A, Kraus T, Suchorska B, et al. TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas. J Neurooncol. 2018;139(3):671–678. - PubMed
1. Goutagny S, Nault JC, Mallet M, et al. High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression. Brain Pathol. 2014;24(2):184–189. - PMC - PubMed